Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Oct 30;109(44):18102-7.
doi: 10.1073/pnas.1206952109. Epub 2012 Oct 17.

Marked difference in saxitoxin and tetrodotoxin affinity for the human nociceptive voltage-gated sodium channel (Nav1.7) [corrected]

Affiliations

Marked difference in saxitoxin and tetrodotoxin affinity for the human nociceptive voltage-gated sodium channel (Nav1.7) [corrected]

James R Walker et al. Proc Natl Acad Sci U S A. .

Erratum in

  • Proc Natl Acad Sci U S A. 2012 Dec 26;109(52):21551

Abstract

Human nociceptive voltage-gated sodium channel (Na(v)1.7), a target of significant interest for the development of antinociceptive agents, is blocked by low nanomolar concentrations of (-)-tetrodotoxin(TTX) but not (+)-saxitoxin (STX) and (+)-gonyautoxin-III (GTX-III). These findings question the long-accepted view that the 1.7 isoform is both tetrodotoxin- and saxitoxin-sensitive and identify the outer pore region of the channel as a possible target for the design of Na(v)1.7-selective inhibitors. Single- and double-point amino acid mutagenesis studies along with whole-cell electrophysiology recordings establish two domain III residues (T1398 and I1399), which occur as methionine and aspartate in other Na(v) isoforms, as critical determinants of STX and gonyautoxin-III binding affinity. An advanced homology model of the Na(v) pore region is used to provide a structural rationalization for these surprising results.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig. 1.
Fig. 1.
Whole-cell voltage-clamp electrophysiology measurements of STX and TTX against rNav1.4 and hNav1.7. (A) Langmuir isotherms of STX and TTX binding to recombinant rNav1.4 and hNav1.7 expressed in CHO cells; error bars represent SD for n ≥ 3. (B and C) Representative normalized current vs. time plots of hNav1.7 varying TTX and STX concentrations, which highlight the reduced potency of STX for inhibition of hNav1.7. Additional normalized current vs. time plots for STX binding are provided in Fig. S1.
Fig. 2.
Fig. 2.
Homology model-derived images highlighting differences between rNav1.4 and hNav1.7. STX bound in site 1 of the α-subunit of the homology model of rNav1.4 is viewed from (A) above and (B) the side of the pore. The four domains of the pore are shown in cartoon representations and colored green (domain I), cyan (domain II), magenta (domain III), and yellow (domain IV). In B, residues comprising the DEKA selectivity filter are displayed as space-filling models; atoms are colored red (oxygen), blue (nitrogen), white (hydrogen), yellow (sulfur), and green (STX carbons) or white (protein carbons). In C–H, STX is docked into rNav1.4 (C) and the identical pose in hNav1.7 (D) to highlight the steric differences of the M1240T and D1241I variations. In C and D, STX is colored similarly as in A and B. The molecular surface of the protein is in white, with M1240 (C) or T1398 (D) shown in yellow and D1241 (C) or I1399 (D) in red. Electrostatic potential surfaces of rNav1.4 (E), hNav1.7 T1398M-I1399D (F), rNav1.4 M1240T-D1241I (G), hNav1.7 (H); depicted range is from −20 (red) to +5 kT (blue). In each image, residues 1,240 (1,398) and 1,241 (1,399) are displayed as stick figures.
Fig. 3.
Fig. 3.
Electrostatic potential surfaces from −4 (red) to 4 kT (blue) of the toxins (A) TTX, (B) STX, and (C) GTX-III highlighting the differences in charge distributions between the molecules.

References

    1. Catterall WA, Goldin AL, Waxman SG. International Union of Pharmacology International Union of Pharmacology. XXXIX. Compendium of voltage-gated ion channels: Sodium channels. Pharmacol Rev. 2003;55(4):575–578. - PubMed
    1. Novella SP, Hisama FM, Dib-Hajj SD, Waxman SG. A case of inherited erythromelalgia. Nat Clin Pract Neurol. 2007;3(4):229–234. - PubMed
    1. Cox JJ, et al. An SCN9A channelopathy causes congenital inability to experience pain. Nature. 2006;444(7121):894–898. - PMC - PubMed
    1. Williams BS, et al. Characterization of a new class of potent inhibitors of the voltage-gated sodium channel Nav1.7. Biochemistry. 2007;46(50):14693–14703. - PubMed
    1. Schmalhofer WA, et al. ProTx-II, a selective inhibitor of NaV1.7 sodium channels, blocks action potential propagation in nociceptors. Mol Pharmacol. 2008;74(5):1476–1484. - PubMed

Publication types

MeSH terms